Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
äŒæ¥ã³ãŒãGKOS
äŒç€ŸåGlaukos Corp
äžå Žæ¥Jun 25, 2015
æé«çµå¶è²¬ä»»è
ãCEOãBurns (Thomas William)
åŸæ¥å¡æ°995
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Jun 25
æ¬ç€Ÿæåšå°1 Glaukos Way
éœåžALISO VIEJO
蚌åžååŒæNASDAQ OMX NASDAQ Basic NYSE
åœUnited States of America
éµäŸ¿çªå·92656
é»è©±çªå·19493679600
ãŠã§ããµã€ãhttps://www.glaukos.com
äŒæ¥ã³ãŒãGKOS
äžå Žæ¥Jun 25, 2015
æé«çµå¶è²¬ä»»è
ãCEOãBurns (Thomas William)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã